Zenith Epigenetics

in response to SanFrancisco99's message

Well, they have at least one event planned that they haven't "confirmed" yet. Poster presentation on November 30th.

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

November 29 – December 2, 2016; Munich, Germany

The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies

S. Attwell, K. Norek, R. Jahagirdar, C. Calosing, S. Lakhotia, E. Campeau, H. Hansen

Please login to post a reply
BearDownAZ
City
Madison, WI
Rank
President
Activity Points
6217
Rating
Your Rating
Date Joined
05/06/2015
Social Links
Private Message
Zenith Epigenetics
Symbol
ZZXY
Exchange
OTCBB
Shares
125,207,692
Industry
Technology & Medical
Create a Post